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        IL-12 and IL-23, two heterodimeric cytokines 
produced by APCs, are composed of a specifi  c 
polypeptide, namely p35 for IL-12 and p19 for 
IL-23, disulfi  de linked to a common p40 chain 
to form the biologically active molecules (  1, 2  ). 
Although p19 and p35 are not secreted in the 
absence of the p40 chain, a consistent amount 
of free p40, whose biological function is still 
debated (  3  ), is produced, often in large excess 
over the complete IL-12 and IL-23 heterodi-
meric proteins (  4  ). The function of IL-12 is 
pivotal in both innate and acquired immunity, 
because it induces IFN-     production from NK 
and NKT cells in the early phases of the immune 
response, and induces the diff  erentiation of Th1 
cells, relevant in protection against infectious 
agents and tumor surveillance (  5  ). A protec-
tive role for the Th1 response generated by 
IL-12/IL-23 has been suggested based on Men-
delian susceptibility to mycobacterial and other 
infectious diseases in children with genetic de-
fects of the IL-12/23  –  IFN-     circuit (  6  ). Studies 
using p19      /      or p35      /      mouse models of auto-
immunity (  7  –  9  ), tumors (  10  ), and infl  ammatory 
bowel disease (  11  –  14  ) have identifi  ed IL-23, 
rather than IL-12, as the major factor responsi-
ble for lesions caused by chronic infl  ammation, 
acting through the induction of a CD4  +   T 
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  We analyzed interleukin (IL) 12 and IL-23 production by monocyte-derived dendritic cells 
(mono-DCs).   Mycobacterium tuberculosis   H37Rv and zymosan preferentially induced IL-23. 
IL-23 but not IL-12 was effi  ciently induced by the combination of nucleotide-binding 
oligodimerization domain and Toll-like receptor (TLR) 2 ligands, which mimics activation by 
  M. tuberculosis  , or by the human dectin-1 ligand     -glucan alone or in combination with 
TLR2 ligands, mimicking induction by zymosan. TLR2 ligands inhibited IL-12 and increased 
IL-23 production. DC priming with interferon (IFN)      strongly increased IL-12 production, 
but was not required for IL-23 production and inhibited IL-23 production induced by 
    -glucan. The pattern of IL-12 and IL-23 induction was refl  ected in accumulation of the 
IL-12p35 and IL-23p19 transcripts, respectively, but not IL-12/23p40. Although IL-23, 
transforming growth factor     , and IL-6 contained in the supernatants of activated mono-
DCs played a role in the induction of IL-17 by human CD4  +   T cells, IL-1    , in combination 
with one or more of those factors, was required for IL-17 production, and its production 
determined the differential ability of the stimuli used to elicit mono-DCs to produce solu-
ble factors directing IL-17 production. Thus, the differential ability of pathogens to induce 
antigen-presenting cells to produce cytokines regulates the immune response to infection. 1448 IL-12 AND IL-23 PRODUCTION IN HUMAN DENDRITIC CELLS | Gerosa et al.
immunoprecipitation and by ELISA. Because IL-12 is prefer-
entially induced by a combination of TLR ligands, DCs were 
also stimulated with the TLR7/8-ligand R848 alone or in 
combination with H37Rv. 
  H37Rv induced IL-12 p75 and IL-23 production in 
IFN-      –  primed peripheral blood CD1c  +   DCs, as detected 
by immunoprecipitation (  Fig. 1 A  ).   R848 synergized with 
H37Rv for IL-12 p75 production but consistently decreased 
IL-23 production. In contrast, LPS and R848 synergisti-
cally induced IL-12 p75 and IL-23 in either untreated or 
IFN-      –  pretreated monocytes and, at higher levels, CD1c  +   DCs 
(Fig. S3, available at http://www.jem.org/cgi/content/full/
jem.20071450/DC1). 
  In mono-DCs, H37Rv induced IL-23 but not IL-12 p75, 
as detected by immunoprecipitation (  Fig. 1 B  ). In IFN-      –
  primed mono-DCs, H37Rv alone induced relevant produc-
tion of both IL-23 and IL-12 p75. The combination of H37Rv 
and R848 did not increase the amount of IL-23 production 
but synergistically induced IL-12 p75 production in both 
IFN-      –  primed and unprimed mono-DCs. 
  ELISA using mono-DC preparations obtained from 20 
diff  erent donors confi  rmed the immunoprecipitation data 
(  Fig. 1 C  ). H37Rv alone was unable to induce production of 
IL-12 p75 in mono-DCs but was eff  ective when added either 
together with R848 (H37Rv+R848 versus R848; P = 0.005) 
or to IFN-      –  primed mono-DCs (H37Rv+IFN-     vs. IFN-    ; 
P = 0.004). Signifi  cantly higher levels of IL-12 were produced 
when IFN-      –  primed mono-DCs were co-stimulated with 
H37Rv and R848 (H37Rv+R848+IFN-     vs. H37Rv+IFN-    ; 
P = 0.001). Unlike IL-12, IL-23 was signifi  cantly induced 
by H37Rv alone (P = 0.005), and its production was only 
modestly increased by the combination of H37Rv and R848. 
IFN-     priming increased IL-23 production (H37Rv+IFN-     
vs. H37Rv; P = 0.001), with no further sizable increase 
upon combination with R848. Like IL-23, IL-10 was in-
duced in response to H37Rv alone (P = 0.052), and its pro-
duction was moderately increased by R848 but reduced by 
IFN-     priming. 
  Overall, these results indicate that   M. tuberculosis   effi   ciently 
induces IL-23 production but is only a modest stimulus for 
IL-12; however, it provides signals to DCs that effi   ciently 
synergize with the TLR7/8 ligand R848 in inducing IL-12 
production. Because DCs produced IL-12 and IL-23 much 
more effi   ciently than did monocytes, and because mono-DCs 
closely mimicked the responses observed with purifi  ed blood 
CD1c  +   DCs, all subsequent experiments in this study were 
performed using mono-DCs. 
  Combination of ligands for nucleotide-binding 
oligodimerization domain (NOD2) and TLR2 mimics 
IL-23 and IL-12 induction by   M. tuberculosis   
  DCs reportedly recognize   M. tuberculosis   primarily through 
TLR2, TLR9, NOD2, and possibly TLR4 (  23  –  27  ). Because 
human mono-DCs do not express functional levels of TLR9, 
we tested whether the association of the NOD2 ligand mur-
amyl dipeptide (MDP) with ligands for TLR2 might mimic 
lymphocyte subset producing IL-17, and through other less-
characterized mechanisms of innate immunity. In humans, a 
role for IL-23 in chronic infl   ammation has been proposed 
based on the association of polymorphisms in the IL-23 recep-
tor gene with Crohn  ’  s disease (  15  ). 
  Products from microorganisms are strong inducers of IL-12 
heterodimer production from APCs that have been exposed to 
cytokines such as IFNs or IL-4, whereas in the absence of these 
mediators, IL-12 production is minimal, although high levels 
of free p40 are induced (  5  ). Until now, very little has been 
known about the stimuli inducing p19 expression and IL-23 
production. Cells of the innate immune system recognize mi-
croorganisms through a limited number of germline-encoded 
pattern recognition receptors (PRRs), (  16, 17  ). The simulta-
neous engagement of distinct PRRs often cooperates in the 
innate response to microorganisms or their products, infl  uenc-
ing both the magnitude and the quality of the immune re-
sponse (  18, 19  ). The synergistic eff  ect of the engagement of 
cooperating Toll-like receptor (TLR) 7/8 and TLR3 or TLR4 
(  20, 21  ) is, however, particularly dramatic for the production 
of the biologically active heterodimeric form of IL-12. 
  In the present study, we observed that although PRR li-
gand  –  activated DCs represent the major producers of IL-12 
and IL-23 among peripheral APCs, there are striking diff  er-
ences in the conditions leading to the expression of either cyto-
kine because of the selective engagement of distinct combinations 
of PRRs and to the diff  erential eff  ect of IFN-     priming of the 
DCs. We also found that the ability of the supernatants of 
activated DCs to induce IL-17 production from naive CD4  +   
T cells is caused by the diff  erential secretion of IL-1    , which 
acts in cooperation with IL-23 and other cytokines. 
    RESULTS   
  Identifi  cation of IL-12, IL-23, and free IL-12 p40 
by immunoprecipitation 
  Immunoprecipitation experiments in IFN-      –  primed, LPS-
stimulated monocyte-derived DCs (mono-DCs) and monocyte-
enriched PBMCs biosynthetically labeled with [  35  S]methionine 
with anti  –  IL-23 p19, anti  –  IL-12 p35, and anti  –  IL-12/23 
p40 mAbs (Fig. S1, available at http://www.jem.org/cgi/
content/full/jem.20071450/DC1) allowed clear identifi  ca-
tion of the IL-12 p40 secreted alone or in association with 
p35 and p19 to form the heterodimeric cytokines IL-12 and 
IL-23. IL-23 appears as three major bands of 61, 57, and 51 kD, 
corresponding to the p19 chain disulfi  de linked to all of 
the glycosylation variants of the IL-12/23 p40 chain (  22  ). 
  Inhibition of glycosylation by tunicamycin (Fig. S2) demon-
strated that   N  -glycosylation of IL-23 is not needed for secretion 
of this cytokine, unlike the fundamental role of   N  -glycosylation 
for secretion of IL-12 p75 (  22  ). 
  Differential regulation of IL-12 and IL-23 production 
by inactivated   Mycobacterium tuberculosis   alone 
or in combination with other stimuli 
  IL-12 and IL-23 production by human DCs stimulated with 
heat-killed   M. tuberculosis   (H37Rv strain) was evaluated by JEM VOL. 205, June 9, 2008 
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No IL-12 production and lower production of IL-23 and IL-10 
in all conditions were observed when non  –  IFN-      –  primed 
mono-DCs were used (unpublished data). 
  These data suggest that the combination of ligands for 
NOD2 and TLR2, known to be present in H37Rv, closely 
mimics the ability of   M. tuberculosis   to induce robust IL-23 
production and, less effi   ciently, IL-12 production. The es-
sential role of NOD2 in response to H37Rv was confi  rmed 
by the complete absence of production of IL-12, both p75 
and p40, in IFN-      –  primed mono-DCs from three Crohn  ’  s 
disease patients homozygous for a frameshift mutation (1,007 fs) 
of the NOD2 gene (NOD2      /     ) (  28  ) stimulated by H37Rv 
alone (Fig. S4, available at http://www.jem.org/cgi/content/
full/jem.20071450/DC1). 
  Although ligands for TLR7/8 have not been identifi  ed in 
  M. tuberculosis  , mycobacterial DNA is a ligand for TLR9 (  23  ), 
an MyD88-coupled receptor with signaling properties similar 
to those of TLR7/8 and expressed on mouse but not human 
DCs. Because the combination of a NOD2 ligand with the 
the stimulation observed with   M. tuberculosis  . Indeed, MDP 
together with the TLR2/6 ligand Pam2C (  Fig. 2 A  ) or the 
TLR1/2 ligand Pam3C (  Fig. 2 B  ) induced production of IL-23, 
IL-12 p75, and free p40 in IFN-      –  primed mono-DCs.   
Treatment with each stimulus alone did not induce IL-23 
and induced only barely detectable amounts of IL-12 p75 and 
free p40. The combination of MDP with R848 induced 
much higher levels of IL-12 p75 but lower levels of IL-23 
than did the combination of MDP with Pam2C or with 
Pam3C that preferentially induced IL-23. R848 and Pam2C 
(  Fig. 2 A  ) or Pam3C (  Fig. 2 B  ) modestly increased IL-12 but 
not IL-23 production. The association of MDP+Pam2C or 
MDP+Pam3C with R848 (  Fig. 2, A and B  , respectively) 
further increased IL-12 p75 and p40, whereas IL-23 remained 
highly expressed and almost unmodifi  ed, a pattern consistent 
with that observed in mono-DCs stimulated by H37Rv and 
H37Rv+R848. These results were confi  rmed by ELISA quan-
titation of cytokine secretion (  Fig. 2 C  ) and by QuantiGene 
multiplex assay to measure mRNA accumulation (  Fig. 2 D  ). 
    Figure 1.         Differential regulation of IL-12 and IL-23 production in CD1c  +   DCs and mono-DCs stimulated by H37Rv  . CD1c  +   DCs (A) and mono-
DCs (B and C) were treated with IFN-     or left untreated. Cells were labeled with [  35  S]methionine (A and B) or unlabeled (C) and stimulated with heat-killed 
H37Rv, alone or together with R848. After 18 h, supernatants were immunoprecipitated with anti  –  IL-12 p35, anti  –  IL-23 p19, or anti  –  IL-12/23 p40 mAbs 
and resolved by nonreducing SDS-PAGE (A and B) or tested for IL-12 p75, IL-23, and IL-10 production by ELISA (C). In A, supernatants were pooled from 
cells purifi  ed from three different donors. Results in B are representative of six independent experiments. Data in C are mean   ±   SE values for mono-DCs 
derived from 20 different donors.     1450 IL-12 AND IL-23 PRODUCTION IN HUMAN DENDRITIC CELLS | Gerosa et al.
    Figure 2.         A combination of NOD2 and TLR2 ligands mimics IL-23 and IL-12 induction by   M. tuberculosis  .   mono-DCs treated with IFN-     were 
labeled with [  35  S]methionine (A and B) or unlabeled (C and D) and stimulated with different combinations of MDP, Pam2C, and Pam3C, with or without 
R848. After 18 h, supernatants were immunoprecipitated with anti  –  IL-12 p35, anti  –  IL-23 p19, or anti  –  IL-12/23 p40 mAbs and resolved in nonreducing 
SDS-PAGE (A and B), or were evaluated for IL-12 p75, IL-23, and IL-10 by ELISA (C). In D, cells were lysed at 3, 6, and 12 h, and mRNA accumulation was 
determined using the QuantiGene multiplex assay. Results in A and B are representative of those obtained in three independent experiments with cells 
derived from different donors. Data in C are mean   ±   SE values from mono-DCs derived from three different donors. Results in D were obtained with cells 
from two different donors and are expressed as the mean   ±   SD of triplicate cultures. Inverted triangles indicate not done.     JEM VOL. 205, June 9, 2008 
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  Combination of ligands for dectin-1 and TLR2 mimics IL-23 
and IL-12 induction by zymosan 
  TLR2 and the     -glucan receptor (human dectin-1) have 
been previously described as the two major PRRs involved 
in the stimulation of DCs by zymosan (  29, 30  ). To assess 
the relative contribution of these PRRs, we tested the abil-
ity of purifi  ed ligands of these receptors to mimic zymosan 
induction of IL-12 and IL-23 production in mono-DCs. As 
observed by both immunoprecipitation (  Fig. 4 A  ) and ELISA 
(  Fig. 4 B  ),     -glucan alone induced production of IL-23 and 
free p40, but not IL-12 p75, analogous to the pattern observed 
in zymosan-stimulated mono-DCs.   IL-12 p75 production 
was observed only when mono-DCs were stimulated by 
    -glucan in association with R848, a condition in which 
IL-23 and free p40 production were also increased (  Fig. 4, 
A and B  ). Stimulation of mono-DCs with     -glucan also 
induced production of IL-10, as previously reported by 
others (  31, 32  ), and this production was increased by R848 
(  Fig. 4 B  ). 
  IFN-     priming of mono-DCs signifi  cantly enhanced IL-
12 p75 production induced by     -glucan (P = 0.018;   Fig. 4, 
A and B  ), similar to the observations with zymosan. However, 
priming of mono-DCs with IFN-     drastically inhibited IL-23 
and IL-10 expression induced by     -glucan (  Fig. 4, A and B  ). 
IL-10 production was signifi  cantly (P   <   0.02) lower in IFN-      –
  primed DCs in response to     -glucan alone or in combination 
with either R848 (  Fig. 4 B  ) or Pam2C (not depicted). IL-23 
induction by     -glucan was signifi  cantly lower in IFN-      –
  primed cells from a large panel of donors (P = 0.02;   Fig. 4 C  ). 
Dectin-1 expression detected by immunofl  uorescence did 
not diff  er between IFN-      –  primed and unprimed mono-DCs 
(unpublished data), indicating that the reduced IL-23 and IL-10 
production in IFN-      –  primed mono-DCs was not dependent 
on dectin-1 downmodulation. Note that co-stimulation of 
mono-DCs with     -glucan and Pam2C, a ligand for TLR2 
that is the other major receptor involved in the recognition of 
zymosan, reversed the inhibition of IL-23 production ob-
served after IFN-     priming (  Fig. 4 D  ). 
  mRNA accumulation closely paralleled the pattern of 
protein expression (  Fig. 4 E  ). Transcripts of the gene encod-
ing the IL-12/23 common p40 chain accumulated in response 
to either single or combined PRR ligands tested. Accumu-
lation of IL-23 p19 and IL-10 transcripts was similarly regu-
lated, with strong accumulation induced by     -glucan and 
enhanced when either R848 or Pam2C was associated with 
    -glucan; IFN-     priming of mono-DCs decreased both 
IL-23 p19 and IL-10 mRNA accumulation in response to 
these ligands. Accumulation of IL-12 p35 transcripts was 
strictly dependent on IFN-     priming of mono-DCs, with 
maximal levels in IFN-      –  primed mono-DCs stimulated 
with a combination of     -glucan and R848. The mRNA 
accumulation data show that the pattern of IL-12 and IL-23 
induction was refl  ected in accumulation of the IL-12p35 
and IL-23p19 transcripts, respectively, but not IL-12/23p40. 
However, the analysis of mRNA at three diff  erent time 
points showed that the mRNA accumulation peaks earlier 
TLR7/8 ligand R848 was much more effi   cient  than  the 
combination with a TLR2 ligand in inducing IL-12 produc-
tion, the combination of NOD2 ligands with mycobacterial 
DNA may represent a strong stimulus for IL-12 induction by 
  M. tuberculosis   in mouse DCs. 
  Differential regulation of IL-12 and IL-23 production 
by zymosan 
  High concentrations of zymosan (200  μ  g/ml) induced mono-
DCs to produce IL-23 and low levels of free p40 but no IL-
12 p75, as detected by immunoprecipitation (  Fig. 3 A  ).   Lower 
amounts of zymosan (10   μ  g/ml) stimulated only free p40 
production in mono-DCs. The association of zymosan with 
R848 induced IL-12 p75 and increased the amount of IL-23 
and free p40. Note that the amount of IL-12 p75 detected in 
response to zymosan at 10   μ  g/ml combined with R848 was 
much higher than that observed in response to zymosan at 
200   μ  g/ml combined with R848, whereas the opposite was 
observed with IL-23. Priming of mono-DCs with IFN-     
enhanced IL-12 p75, IL-23, and free p40 production in 
response to zymosan, either in the presence or absence of 
R848. Again, the amount of IL-12 p75 induced by zymosan 
at 10   μ  g/ml was consistently higher than that induced by 
  zymosan at 200   μ  g/ml. 
  Evaluation of cytokine production by ELISA (  Fig. 3 B  ) 
confi  rmed that zymosan induced IL-12 p75 production only 
when used in association with R848 or when mono-DCs 
were primed with IFN-    . The amount of IL-12 p75 induced 
by zymosan at 10   μ  g/ml was signifi  cantly higher than that in-
duced by zymosan at 200   μ  g/ml, either associated with R848 
(P = 0.012) or in IFN-      –  primed cells (P = 0.01). Maximal 
IL-12 production was observed when IFN-      –  primed mono-
DCs were stimulated with both R848 and low-concentra-
tion zymosan (10 vs. 200   μ  g/ml zymosan; P = 0.011). Unlike 
the observation for IL-12, high levels of IL-23 were induced 
by zymosan alone at 200   μ  g/ml, and these levels were not 
signifi  cantly modifi  ed by R848 or by IFN-     priming. At 10 
  μ  g/ml, zymosan induced much lower levels of IL-23 than at 
200   μ  g/ml (P = 0.026), but these were signifi  cantly increased 
by R848 co-stimulation (P = 0.01) or IFN-     priming (P = 
0.002). IL-10 production was induced in mono-DCs by 
zymosan alone at 200   μ  g/ml or by zymosan at 10   μ  g/ml in 
association with R848; production induced at the high con-
centration of zymosan was reduced when mono-DCs were 
primed with IFN-     either in the absence (P = 0.047) or pres-
ence (P = 0.016) of R848. 
  Thus, zymosan is a potent inducer of IL-23 and IL-10 in 
a dose-dependent way. IFN-     priming of DCs inhibited IL-10 
production induced by zymosan, whereas it had no eff  ect on 
the induction of IL-23 by high-dose zymosan. Unlike IL-23, 
IL-12 was poorly induced by zymosan, which paradoxically 
induced the latter cytokine in IFN-      –  primed mono-DCs 
only when used at low concentrations. However, zymosan 
was strongly synergistic with R848 in inducing IL-12, an eff  ect 
that was again more effi   cient at lower concentrations of zymosan 
and was amplifi  ed in IFN-      –  primed mono-DCs. 1452 IL-12 AND IL-23 PRODUCTION IN HUMAN DENDRITIC CELLS | Gerosa et al.
  TLR2 ligands inhibit IL-12 production by mono-DCs induced 
by combinations of other PRR ligands 
  When the combination of     -glucan and R848 was further 
associated with Pam2C, IL-12 p75 production by untreated 
or IFN-      –  primed mono-DCs was drastically inhibited and 
IL-12 p40 was minimally decreased, whereas IL-23 was con-
sistently increased (  Fig. 5 A  ).   To further investigate the in-
hibitory eff  ect of TLR2 ligands on IL-12 p75 production, 
mono-DCs from several donors were incubated with LPS, 
    -glucan, or low-dose zymosan in association with R848, 
three ligand combinations that strongly induced IL-12 p75 
production in the presence or absence of Pam2C (  Fig. 5 B  ). 
Pam2C strongly inhibited IL-12 p75 production induced by 
zymosan and R848 (P = 0.006) or by     -glucan and R848 
(P = 0.007), whereas IL-12 p75 production induced by LPS and 
R848 was moderately reduced (P = 0.012). In contrast, IL-10 
was increased (zymosan+R848, P = 0.019;     -glucan+R848, 
P = 0.002) or unaff  ected (LPS+R848) by treatment with 
Pam2C. The lower sensitivity of IL-12 p75 induced by 
LPS+R848 to inhibition by TLR2-ligands was confi  rmed by 
the observation that 50 ng/ml Pam2C was required for 75% 
inhibition of the IL-12 p75 induced by LPS+R848, whereas 
5 and 0.5 ng/ml were suffi   cient for   >  75% inhibition of the 
IL-12 p75 production induced by     -glucan+R848 and by 
zymosan+R848, respectively (  Fig. 5 C  ). The three synthetic 
when DCs are stimulated with TLR ligands (  Fig. 4 E   and 
not depicted) than when they are stimulated or co-stimu-
lated with     -glucan. Although the amount of mRNA accu-
mulation provides important information on the degree 
and kinetics of the expression of the genes encoding the 
heterodimeric cytokines, even when analyzed at diff  erent 
time points it may not give a full account of the total amount 
of transcripts available for translation during the period 
of stimulation. Thus, the analysis of p35 and p19 mRNA 
accumulation that has often been used in past reports to 
evaluate IL-12 and IL-23 production is less representative 
than the analysis of protein accumulation in the superna-
tant fl  uids at the end of the stimulation for evaluating the 
transcriptional and posttranscriptional regulation of cyto-
kine production. 
  These results show that unlike high-dose zymosan, stim-
ulation with     -glucan alone induces IL-23 production in 
nonprimed mono-DCs but does so poorly in IFN-      –  primed 
DCs. However, the association of     -glucan with Pam2C en-
hanced IL-23 production by nonprimed mono-DCs of most 
donors and signifi  cantly reversed the inhibition of IL-23 pro-
duction observed in the IFN-      –  primed cells. Thus, like high 
doses of zymosan, the combination of dectin-1 and TLR2 
ligands results in elevated IL-23 production independent of 
IFN-     priming. 
    Figure 3.         Differential regulation of IL-12 and IL-23 in mono-DCs stimulated by zymosan.   mono-DCs treated with or without IFN-     were  la-
beled with [  35  S]methionine (A) or unlabeled (B) and stimulated with 10 or 200   μ  g/ml zymosan alone or associated with R848. After 18 h, supernatants 
were immunoprecipitated with anti  –  IL-12 p35, anti  –  IL-23 p19, or anti  –  IL-12/23 p40 mAbs and resolved in nonreducing SDS-PAGE (A) or were tested by 
ELISA (B) for IL-12 p75, IL-23, and IL-10. Results in A are representative of three independent experiments. Results in B are mean   ±   SE values from 
mono-DCs derived from 10 different donors.     JEM VOL. 205, June 9, 2008 
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    Figure 4.         Role of dectin-1 and TLR2 in IL-12 and IL-23 production in mono-DCs.   mono-DCs treated with IFN-     or left untreated were labeled 
with [  35  S]methionine (A) or unlabeled (B  –  E) and stimulated with     -glucan or Pam2C, or with a combination of     -glucan+Pam2C, with or without R848. 
After 18 h, supernatants were immunoprecipitated with anti  –  IL-12 p35, anti  –  IL-23 p19, or anti  –  IL-12/23 p40 mAbs and resolved in nonreducing SDS-
PAGE (A) and tested for IL-23, IL-12 p75, and IL-10 production by ELISA (B  –  D) and for mRNA accumulation using the QuantiGene multiplex assay (E). 
Results in A are representative of four independent experiments. Results in B are mean   ±   SE values from mono-DCs derived from 18 donors. Results in C 
represent individual IL-23 levels from mono-DCs derived from 21 different donors. Results in D are mean   ±   SE values from fi  ve experiments. Results in E 
are mean   ±   SD (  n   = 3) mRNA accumulation in cells derived from three separate donors and lysed at 3 h (right column of each triplet), 6 h (middle column 
of each triplet), and 12 h (right column of each triplet). Inverted triangles indicate not done.     
ligands 2-kD macrophage-activating lipopeptide (MALP-2), 
Pam2C (both TLR2/TLR6 ligands), and Pam3C (TLR2/
TLR1 ligand) all showed a strong, dose-dependent capacity 
to inhibit IL-12 p75 production induced by zymosan+R848 
or by     -glucan+R848. MALP-2 and Pam2C, were, however, 
more potent than Pam3C (  Fig. 5 D  ). 
  The ability of TLR2 ligands to inhibit IL-12 p75 but not 
IL-23 production induced by     -glucan+R848 might explain 1454 IL-12 AND IL-23 PRODUCTION IN HUMAN DENDRITIC CELLS | Gerosa et al.
    Figure 5.         TLR2-mediated inhibition of IL-12 p75.   (A) mono-DCs treated with IFN-     or left untreated were labeled with [  35 S]methionine  and 
stimulated with     -glucan, Pam2C, R848, and their combinations. After 18 h, supernatants were immunoprecipitated with anti  –  IL-12 p35, anti  –  IL-
23 p19, or anti  –  IL-12/23 p40 mAbs and resolved in nonreducing SDS-PAGE. (B) Cytokine production was measured by ELISA in mono-DCs 18 h 
after stimulation with 10 ng/ml LPS+R848, 10   μ  g/ml     -glucan+R848, or 10   μ  g/ml zymosan+R848 in the presence or absence of 50 ng/ml Pam2C 
(each symbol represents a single donor). (C) mono-DCs were stimulated as indicated in B in the presence or absence of 0.5, 5, and 50 ng/ml 
Pam2C, and IL-12 p75 was measured by ELISA (mean   ±   SD from triplicate cultures). (D) IL-12 p75 production was assessed by ELISA (mean   ±   SD 
from triplicate cultures) in mono-DCs stimulated with 10   μ  g/ml zymosan+R848 or 10   μ  g/ml     -glucan+R848 without or with 2, 20, and 200 ng/ml 
Pam3C; 1, 10, and 100 ng/ml MALP-2; or 0.5, 5, and 50 ng/ml Pam2C. (E) mono-DCs were stimulated with10   μ  g/ml zymosan+R848 (left) or with 
0.1   μ g/ml     -glucan+R848 (right) in the absence (open column) or presence (gray column) of 30   μ  g/ml of the neutralizing anti  –  IL-10 mAb 19F1, 
with or without 50 ng/ml Pam2C. Cytokines were measured by ELISA (mean values from duplicate cultures in a representative experiment of six 
performed with similar results).     JEM VOL. 205, June 9, 2008 
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Antibody 20C2, which blocks the biological activity of IL-12 
but not of IL-23, completely inhibited IFN-     but not IL-17 
production, whereas anti  –  IL-12 p40 antibody C8.6, which 
inhibits both IL-12 and IL-23, completely inhibited IFN-     
production but only half of IL-17 production (P = 0.0002 
and 0.013 for zymosan and     -glucan, respectively;   Fig. 6 B  ). 
We therefore turned to TGF-     and IL-6. Antibodies neu-
tralizing TGF-     and IL-6, two cytokines shown to be essen-
tial for IL-17 production in mice (  33  ), each partially inhibited 
IL-17 production and, in combination, induced profound 
inhibition of IL-17, whereas these antibodies, alone or in 
combination, resulted in increased production of IFN-     (  Fig. 
6 C  ). However, IL-6, like IL-23, was present in all three su-
pernatants. IL-1    , another cytokine potentially involved in IL-
17 induction in human CD4  +   T cells (  34  –  36  ), was detected 
in the zymosan- and     -glucan  –  stimulated supernatants but at 
minimal levels in the LPS+R848-stimulated supernatant. 
The use of IL-1     together with recombinant IL-23 or addi-
tion of IL-1     to the supernatant from mono-DCs stimulated 
with LPS+R848 (and from which IL-12 was removed by af-
fi  nity chromatography with anti  –  IL-12 p35 mAb beads) re-
constituted IL-17 production in human naive CD4  +   T cells 
(  Fig. 6 D  ). Also, IL-1RA inhibited IL-17 production induced 
by the supernatants (unpublished data). Thus, although IL-23, 
TGF-    , and IL-6 all appeared to play a role in the induction 
of IL-17 by human CD4  +   T cells, IL-1    , in combination with 
one or more of those factors, was essential in the induction 
of IL-17 production and determined the diff  erential ability of 
the supernatants from activated mono-DCs to direct IL-17 
production by CD4  +   T cells. 
    DISCUSSION   
  The heterodimeric cytokine IL-12 is produced by cells of in-
nate immunity, particularly DCs and macrophages stimulated 
through PRRs and interaction with NK cells or antigen-
activated T cells (  5  ). However, stimulation of individual PRRs 
is not suffi   cient to induce optimal production of the IL-12 
heterodimer; instead, it induces secretion of a large excess of 
the free p40 chain (  4, 20  ). In addition to individual PRR stim-
ulation, exposure of the producer cells to cytokines (e.g., IFN-     
and IL-4) (  37  –  39  ) or co-stimuli (e.g., CD40 ligand) (  40  ), or 
the association of diff  erent TLR ligands (e.g., TLR7/8 or 
TLR9 ligands together with TLR3 or TLR4 ligands) (  18, 20, 
21  ) is required for effi   cient production of the functional IL-12 
heterodimer. These fi  ndings indicate that diff  erent PRR ligands 
expressed by pathogens during an infection cooperate in in-
ducing IL-12 production, which is further regulated by soluble 
products or surface receptor/ligand interaction generated 
during both the innate and immune response to the infection. 
  Like IL-12, the cytokine IL-23 is a heterodimer com-
posed of a specifi  c p19 polypeptide linked to the p40 chain 
shared with IL-12 (  2  ). Previous studies of IL-23 have been 
hampered by the limited methods available to detect ex-
pression at the protein level. SDS-PAGE analysis of immuno-
precipitates with the anti  –  IL-23 p19, anti  –  IL-12 p35, and 
anti-p40 mAbs allowed us to analyze the single components 
the inverse dose  –  response observed in IL-12 p75 but not IL-23 
production induced by zymosan. Indeed, this paradoxical 
dose dependence might refl  ect a diff  erential contribution of 
dectin-1 and TLR2 ligands at diff  erent concentrations of 
zymosan. The dose-dependent production of IL-23 could 
reasonably be attributed to the presence in zymosan of the 
dectin-1 ligand     -glucan, an effi   cient stimulus for IL-23 that 
is augmented by the combination with TLR2 ligands. The 
inhibitory activity for IL-12 but not IL-23 production ex-
erted by the TLR2 ligands also present in zymosan could ac-
count for the decreased IL-12 production when high-dose 
zymosan was used in association with R848. 
  IL-10 is induced by TLR2 ligands but does not account 
for the inhibition of IL-12 p75 production 
  Both zymosan and     -glucan induced production of IL-10 
and accumulation of IL-10 transcripts in mono-DCs, with 
enhanced levels upon co-stimulation with either R848 or 
Pam2C (  Fig. 3 B; Fig. 4, B and E  ; and not depicted). To de-
termine whether autocrine IL-10 might underlie the inhibi-
tion of IL-12 p75 and IL-23 production, mono-DCs were 
stimulated with low-dose zymosan+R848 or     -glucan+R848 
in the presence or absence of a neutralizing anti  –  IL-10 mAb 
(  Fig. 5 E  ) and/or exogenously added recombinant IL-10 
(not depicted). Both IL-23 and IL-12 p75 were inhibited by 
both exogenous IL-10 (not depicted) and by autocrine IL-10, 
as demonstrated by the increased production of IL-23 and 
IL-12 p75 in the presence of the neutralizing anti  –  IL-10 
mAb (  Fig. 5 E  ). The inhibitory eff  ect of Pam2C on IL-12 
p75 production was not altered by the neutralizing anti  –  IL-
10 mAb, indicating that IL-10 was not responsible for the 
inhibition. This conclusion is further supported by the fact 
that although IL-10 was able to suppress both IL-12 and 
IL-23 production, Pam2C enhanced IL-23 production while 
suppressing IL-12 production. An anti  –  TGF-     neutralizing 
antibody, alone or together with the anti  –  IL-10 mAb, also 
did not prevent Pam2C inhibition of IL-12 p75 production 
(unpublished data). 
  Induction of IL-17 and IFN-     in human naive CD4  +   T cells 
by supernatants of stimulated human mono-DCs 
  We next investigated whether the supernatants of mono-
DCs stimulated in the conditions leading to maximum IL-23 
production were able to induce IL-17 production in naive 
human CD4  +   T cells stimulated with anti-CD3 and anti-CD28. 
Supernatants from zymosan-,     -glucan  –  , and LPS+R848-
treated cells containing approximately equivalent concentrations 
of IL-23 were tested. Unlike IL-23, IL-12 was undetectable 
in the supernatant from     -glucan  –  stimulated cells; instead, 
IL-12 levels were highest in the LPS+R848 supernatant and 
low in the zymosan supernatants (  Fig. 6 A  ).   The induction of 
IFN-     from naive human CD4  +   T cells correlated with the 
IL-12 content in the supernatants, but only the supernatants 
from zymosan- and     -glucan  –  stimulated mono-DCs, and not 
that from LPS+R848-stimulated mono-DCs, induced IL-17 
production, although all three supernatants contained IL-23. 1456 IL-12 AND IL-23 PRODUCTION IN HUMAN DENDRITIC CELLS | Gerosa et al.
associated with the TLR-7/8 ligand R848, which induced 
maximal expression of IL-12, also induced expression of 
IL-23. However, diff  erential IL-12 and IL-23 expression in 
DCs was triggered by selected associations of PRR ligands 
that mimicked structures associated with microorganisms. 
Our data identify a crucial role for IFN-    , TLR7/8, and 
TLR2 in determining preferential expression of either IL-
12 or IL-23. 
  Early in our studies, we observed that activation of DCs 
with two complex microorganisms  —  heat-killed   M. tuber-
culosis   H37Rv strain and the yeast zymosan  —  effi   ciently in-
duced IL-23 but little or no IL-12 p75. The association of 
the TLR7/8 ligand R848 or IFN-     priming to stimulation of 
DCs with either H37Rv or zymosan induced strong expression 
of the IL-12  –  IL-23 complex, including the free p40 chain, 
and of the assembly of the IL-23 heterodimer. We fi  nd that 
the p19 chain associates as a disulfi  de-linked heterodimer to 
the 34-, 41-, and 44-kD glycosylation variants of the IL-
12/23 p40 chain, analogous to IL-12 p35 (  22  ). However, 
our biochemical analysis revealed a diff  erent sensitivity to 
  N  -linked posttranslational modifi  cations, which are required 
for IL-12 p75 secretion (  22, 41  ) but are irrelevant for IL-23 
secretion. Immunoprecipitation and ELISA analyses indi-
cated some similarities in the regulation of IL-12 and IL-23 
production. Both cytokines were effi   ciently produced by 
freshly purifi  ed peripheral blood DCs and by mono-DCs, 
whereas lower production was observed in monocytes. Many 
of the stimuli (e.g., LPS or poly-(I:C); unpublished data) 
    Figure 6.         Induction of IL-17 and IFN-     in human CD4    +     T cells by supernatants of stimulated mono-DCs.   Supernatants from differently stimu-
lated mono-DCs were used to induce IL-17 and IFN-     production from human CD4  +   CD45RO       T lymphocytes stimulated with anti-CD3 and anti-CD28. 
(A) Supernatants from IFN-      –  primed mono-DCs stimulated with 200   μ  g/ml zymosan or 1   μ  g/ml LPS+R848, or from unprimed mono-DCs stimulated with 
10   μ g/ml     -glucan, were evaluated by ELISA for IL-12, IL23, IL-6, and IL-1     production and for the capacity to induce IL-17 and IFN-     in naive CD4  +   T 
cells (mean   ±   SE from 10 independent experiments). (B) IL-17 and IFN-     production was determined by ELISA in naive T cell cultures in the presence of 
supernatants from zymosan- or     -glucan  –  stimulated mono-DCs, and in the presence or absence of neutralizing anti  –  IL-12 p75 (20C2) or anti-p40 (C8.6) 
mAbs (mean   ±   SE from seven independent experiments). (C) Effect of neutralizing anti  –  TGF-     or anti  –  IL-6, or a mixture of both mAbs on IL-17 and IFN-    
production measured by ELISA in naive T cells cultured in the presence of supernatants from zymosan-stimulated mono-DCs. (D) Effect of 10 ng/ml IL-1    
on IL-17 and IFN-     production, as determined by ELISA in naive T cells cultured in the presence of IL-23 or an IL-12  –  depleted supernatant from 
LPS+R848  –  stimulated mono-DCs. Supernatants were diluted to contain IL-23 at a fi  nal concentration of 15 or 1.5 ng/ml (light and dark gray, respec-
tively). Recombinant IL-23 was used at 15 or 1.5 ng/ml (light and dark gray, respectively). C and D show the mean   ±   SD from triplicate cultures. Similar 
results were obtained in three independent experiments.     JEM VOL. 205, June 9, 2008 
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portant PRR ligands known to be present in zymosan, al-
lowed us to identify TLR2 as a key PRR that diff  erentially 
regulates the expression of IL-12 and IL-23.     -glucan induced 
very high-level IL-23 production in DCs, consistent with results 
recently reported for mouse DCs (  48  ), and production was 
increased two- to threefold by co-stimulation with TLR2 or 
TLR7/8 ligands. However, production of IL-12 p75 was only 
induced by     -glucan and R848 together and not by     -glucan 
alone or in combination with TLR2 ligands. Furthermore, 
the IL-12 production induced by     -glucan and R848, unlike 
that of IL-23, was drastically inhibited by the addition of TLR2 
ligands. Interestingly, IL-23 was preferentially induced by high-
dose zymosan, whereas IL-12 was more effi   ciently induced by 
low-dose zymosan in combination with R848 and/or IFN-    . 
This paradoxical inverse dose dependence is likely explained 
by the diff  erential contribution of dectin-1 and TLR2 ligands 
when zymosan was used at low or high doses. 
  IL-10, which inhibits IL-12 production (  49  ), was also in-
duced by zymosan (  31, 32  ), and its production was enhanced 
by TLR2 ligands, consistent with previous reports (  50  –  52  ). 
However, despite effi   cient inhibition of IL-23 production 
by IL-10, Pam2C inhibited IL-23 production even in the 
presence of a neutralizing anti  –  IL-10 mAb, excluding IL-10 
as a major mechanism mediating the inhibition of IL-12 p75 
by TLR2 ligands. Previous papers described the promotion 
of Th2 and T regulatory cell responses by TLR2 ligands via 
IL-10 production (  52, 53  ). IL-12 p75 favors Th-1 responses 
and prevents the diff  erentiation of other Th subsets, includ-
ing the Th17 subset, promoted by IL-23. Thus, our results 
indicating the IL-10  –  independent inhibition of IL-12 p75 
and enhancement of IL-23 production by TLR2 add a new 
mechanism by which engagement of this receptor can modu-
late the Th responses. 
  IFN-     enhances transcription of genes encoding both 
p40 and p35, and it has a marked eff  ect on production of the 
IL-12 p75 (  54  ). Thus, it seemed reasonable to hypothesize a 
similar enhancing eff  ect of IFN-     on the IL-23 heterodimer. 
Indeed, IFN-     was required for optimal IL-12 and IL-23 
production in mono-DCs stimulated by LPS and in both 
freshly isolated DCs and mono-DCs stimulated by H37Rv 
alone or in association with the TLR7/8 ligand R848. How-
ever, the enhancing eff  ect of IFN-     on IL-23 production was 
dependent on the nature of the PRR triggered, because     -
glucan  –  induced IL-23 production, unlike that of IL-12, was 
eff  ectively inhibited at both the protein and mRNA levels by 
IFN-    . On the other hand, IFN-     enhanced IL-23 induc-
tion by low dose zymosan. Because TLR2 ligands increased 
IL-23 production in both IFN-      –  primed and unprimed cells 
stimulated by     -glucan, it is possible that the diff  erent results 
obtained using     -glucan or zymosan rest in the engagement of 
TLR2 or other PRRs by ligands present in the yeast. IFN-     
inhibited the production of IL-10, as previously reported by 
others using diff  erent inducers (  55  –  57  ). The mechanism by 
which IFN-     inhibits IL-10 involves the GSK3 and CREB/
AP1 transcription factors (  57  ). The fi  nding that both IL-23 
and IL-10 were inhibited by IFN-     raises the possibility of 
of IL-12 p75, with no major eff  ect on IL-23 production. 
Thus, the relative pattern of expression of the two cytokines 
appears to be strictly dependent on the PRRs engaged by 
diff  erent microorganisms, as depicted in the model presented 
in Fig. S5 (available at http://www.jem.org/cgi/content/full/
jem.20071450/DC1). 
  A protective role for IL-23 in   M. tuberculosis   infection 
has recently been described based on its activity in inducing 
a Th17 response and facilitating a memory T cell response 
(  6, 42  –  46  ). The emerging role of IL-23, together with the 
well-known and possibly predominant role of IL-12 and 
IFN-     in the protection against   M. tuberculosis  , suggests that 
a balanced production of IL-23 and IL-12 might be cru-
cial in the defense against this intracellular pathogen (  46  ). 
  M. tuberculosis   H37Rv induced IL-12 p75 in mono-DCs 
only after IFN-     priming and/or co-stimulation with R848, 
whereas IL-23 was induced by H37Rv alone and was mod-
estly aff  ected by co-stimulation. The diff  erential regulation 
of IL-12 p75 and IL-23 was even more striking in IFN-      –
  primed peripheral blood DCs stimulated by H37Rv, in which 
R848 co-stimulation not only strongly increased IL-12 p75 
production but also inhibited IL-23 production. Among the 
PRRs known to recognize mycobacteria (  23  –  27  ), the com-
bined stimulation of TLR2 and NOD2 was described to be 
required for the production of TNF (  25  ). Our results show 
that the association of the NOD2 ligand MDP with the 
TLR2 ligand Pam3C or Pam2C, or with the TLR7/8 ligand 
R848, induced both IL-12 and IL-23 in IFN-      –  primed 
mono-DCs with a striking and reproducible preferential ac-
tivation of IL-12 by the combination of ligands for NOD2 
and TLR7/8, and of IL-23 by the combination of ligands 
for NOD2 and TLR2. The expression pattern of these cyto-
kines induced by the combinations MDP and Pam3C (or 
Pam2C) or MDP and Pam3C (or Pam2C) associated with 
R848 was similar to the pattern induced by H37Rv alone 
or associated with R848, respectively, suggesting that NOD2 
and TLR2 acting together are crucial receptors for IL-12 and 
IL-23 expression in response to   M. tuberculosis  . DCs from 
NOD2      /      patients are impaired for IL-12 production in 
response to H37Rv. In addition to NOD2 and TLR2,   M. 
tuberculosis   expresses heat-labile TLR4 ligands that might be 
involved in cooperating with other PRRs for cytokine in-
duction (  27  ). It is also of interest that in the mouse, TLR9 
plays an important role in IL-12 p40 production, whereas 
TLR2 is mostly responsible for production of TNF (  23  ). 
Human DCs do not express TLR9 (  47  ), possibly explaining 
the relative ineffi   ciency of   M. tuberculosis   to induce IL-12 in 
human DC cultures. Co-stimulation with R848, a ligand for 
the well-expressed TLR8 on human DCs, may mimic the 
eff  ect of the mycobacterial TLR9 ligands on mouse DCs. 
  Like   M. tuberculosis  , the yeast zymosan induced IL-23 
production in the absence of IL-12 p75. Both   M. tuberculosis   
and zymosan also required co-stimulation of DCs with R848 
or IFN-    , or their association, for IL-12 p75 induction. The 
combination of a TLR2 ligand (Pam2C) and the     -glucan 
receptor/dectin-1 ligand     -glucan, which are the most im-1458 IL-12 AND IL-23 PRODUCTION IN HUMAN DENDRITIC CELLS | Gerosa et al.
duction of IL-23 responsible for the chronic infl  ammation 
and the Th17 response associated with this cytokine. In par-
ticular, we found that production of IL-23 is either enhanced 
or inhibited by IFN-     depending on the receptor involved in 
the induction of IL-23. This may have important consequences 
in diff  erent types of infections, e.g., in a mycobacterial infec-
tion in which the presence of a strong Th1 response with 
high IFN-     levels may not prevent the simultaneous or suc-
cessive production of IL-23, although it would likely prevent 
a full-fl  edged Th17 response by acting at the T cell level. In 
fungal infections, the presence of a strong Th1 response may 
also prevent the eff  ective dectin-1  –  mediated stimulation of 
IL-23 production and the generation of Th17 cells acting at 
the APC level. We also fi  nd that ligands for both TLR1/2 
and TLR2/6, when associated with stimulation through NOD2 
or dectin-1, preferentially induce IL-23 rather than IL-12, 
and when associated with several ligand combinations that 
induce IL-12 very effi   ciently, block IL-12 production. The 
very contrasting eff  ect of the diff  erent TLR ligands is exem-
plifi  ed by     -glucan, which alone or in association with TLR2 
ligands induces only IL-23 production, whereas its associa-
tion with R848 represents the most powerful IL-12  –  induc-
ing stimulus reported thus far, even more potent then the 
combination of LPS and R848. In addition to our data indi-
cating that IL-23 and IL-12 are diff  erentially regulated by 
various PRR ligands expressed by microorganisms, we also 
fi  nd that the diff  erential induction of IL-1 production may 
profoundly aff  ect the production of IL-17 and the Th17 re-
sponses. We conclude that both pathogen-intrinsic factors and 
regulatory components of the infl  ammatory and immune re-
sponses likely aff  ect the nature of the initial innate and immune 
responses to the infection, as well as their evolution when the 
infection progresses or resolves. 
  MATERIALS AND METHODS 
  Antibodies.     The following antibodies were affi   nity purifi  ed on Sepharose  –
  protein G (GE Healthcare) and covalently immobilized at 1  –  6 mg/g of 
CNBr-activated Sepharose 4B beads (GE Healthcare): C11.79 mAb and 
C8.6 mAb, recognizing the IL-12      chain (p40) (  38  ); 12H4 mAb, recogniz-
ing the IL-12      chain (p35; provided by S. Wolf, Wyeth Pharmaceuticals, 
Cambridge, MA); and PAB 512 (7G10) and PAB 187 mouse anti  –  human 
IL-23 p19 mIgG1 and mIgG2a, respectively, recognizing the p19 of the 
IL-23 heterodimer (  2  ). To increase binding capacity, C11.79 and C8.6 mAbs 
or 512 and 187 mAbs were coupled as a mixture. 30   μ  g/ml of the neutraliz-
ing anti  –  IL-10 19F1.1 mAb (provided by K. Moore, Schering-Plough Bio-
pharma, Palo Alto, CA), 10   μ  g/ml anti  –  TGF-     1D11 mAb (provided by 
F. Ruscetti, National Cancer Institute, Frederick, MD), and goat anti  –  human 
IL-6 antiserum (1:100) were used in naive T cell cultures. 
  Reagents.     The following reagents were used: 10 ng/ml LPS (or as indi-
cated in the fi  gure legends; Sigma-Aldrich), 1   μ  M R848 (InvivoGen), 10   μ  g/ml 
    -glucan (from baker  ’  s yeast; Sigma-Aldrich), 200 ng/ml Pam3CSK4 
(or as indicated in the fi  gure legends; InvivoGen), 50 ng/ml Pam2CSK4 
(or as indicated in the fi  gure legends; InvivoGen), MALP-2 (Qbiogene), 
10 or 200   μ  g/ml zymosan (from   Saccharomyces cerevisiae  ; InvivoGen), and 
10   μ  g/ml MDP (InvivoGen). Heat-killed   M. tuberculosis   H37Rv was pre-
pared as follows: bacteria were grown in standing cultures in Middlebrook 
7H9 broth (BD Biosciences) supplemented with albumin  –  dextrose com-
plex and 0.05% Tween 80 until the mid-log phase. Cultures were heated 
similarities in the pathways by which dectin-1 induces the 
two genes. 
  A dissociated production of IL-12 and IL-23 was previ-
ously reported for   Candida   yeasts that induced both IL-12 and 
IL-23 compared with the hyphal form that induced only IL-23 
(  58  ). Those data are consistent with previous data in the mouse 
(  59  ) but not with others reported for human DCs, indicating 
an inability of the hyphal form to induce IL-12 (  60  ). Because 
    -glucan is exposed only in the yeast and not in the fi  lamen-
tous form (  61  ), it is possible that receptors other than dectin-1 
play a major role in IL-23 induction by   Candida  . However, the 
ability of zymosan to induce both IL-23 and IL-12 was blocked 
by laminarin (unpublished data), strongly suggesting a major 
role for the     -glucan receptor in the induction of both cyto-
kines by the yeast zymosan. Evidence suggesting an important 
role for the IL-23  –  IL-17 axis, as well as for dectin-1, in anti-
fungal resistance is rapidly emerging (  58, 62  –  65  ). 
  The IL-23  –  containing supernatants from human DCs 
stimulated by zymosan or     -glucan induced production of 
IL-17 in naive human CD4  +   T cells stimulated polyclonally. 
IL-17 production was not aff  ected or slightly enhanced by 
an antibody neutralizing IL-12, whereas it was diminished 
by an antibody to IL-12 p40, neutralizing both IL-12 and 
IL-23. Surprisingly, the supernatant of cells stimulated with 
LPS+R848 that also contained IL-23 failed to induce IL-17 
production. We found that this inability of the LPS+R848-
induced supernatant to induce IL-17 production was caused 
by the absence of high IL-1     concentrations that were pres-
ent in the zymosan- and     -glucan  –  induced supernatants. 
IL-1 was required for IL-17 induction in human CD4  +   cells 
in combination with one or more of the cytokines IL-23, 
TGF-    , and IL-6, as also suggested by other studies (  34  –  36  ), 
and the level of IL-1 produced by the various stimuli used 
in our study was responsible for the diff  erential induction of 
IL-17 production. The ability of the supernatants to induce 
IFN-     production in CD4  +   T cells correlated with their 
content of IL-12, but not of IL-23, and was completely 
blocked by antibodies neutralizing IL-12 p75, thus excluding 
a major role for IL-23 in IFN-     production. IL-1     is also 
required for production of IFN-     by human T cells stimu-
lated by IL-12 (  49  ); however, much lower concentrations of 
IL-1     appear to be required for this eff  ect than those required 
for IL-17 production, and suffi   cient IL-1 is probably present 
in all the supernatants tested or produced in the T cell cultures 
to allow IFN-     production. The anti  –  TGF-     antibody in-
hibits IL-17 production. Previous studies (  35, 36  ) failed to 
observe an eff  ect of added TGF-     on the diff  erentiation of 
human Th17, suggesting that endogenous TGF-     present 
in the cultures was suffi   cient for permitting IL-17 produc-
tion, whereas additional exogenous TGF-     had no eff  ect 
or even inhibited IL-17. The requirement for TGF-     in 
IL-17 production might be partially caused by its inhibiting 
eff  ect on IFN-     production, in addition to a direct eff  ect on 
T cell diff  erentiation. 
  The separate regulation of IL-12 and IL-23 through dif-
ferent associations of PRRs might lead to a preferential pro-JEM VOL. 205, June 9, 2008 
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peptin (Sigma-Aldrich), 10   μ  g/ml antipain (Sigma-Aldrich), 2 mM EDTA, 
and 2 mM iodoacetamide as protease inhibitors. Radiolabeled cells were 
washed by centrifugation in PBS, and the cell pellet was resuspended in TBS 
solution containing 1% Nonidet P-40 and protease inhibitors. After a 1-h 
incubation, lysates were centrifuged at 15,000   g   for an additional 10 min. 
Supernatants and cell lysates were precleared with Sepharose  –  protein A and 
incubated with Sepharose-immobilized mAbs for 2 h with shaking. mAb-
coupled Sepharose beads were recovered by centrifugation and washed se-
quentially with TBS/0.1% Nonidet P-40 (four times) and with 10 mM 
Tris-HCl (pH 8.2) containing 0.1% Nonidet P-40 (twice). Immuno-
precipitated materials were eluted from the beads by heating at 100  °  C for 
4 min in SDS-PAGE sample buff  er. 
  SDS-PAGE and isolation of proteins.     [  35  S]methionine-labeled specifi  c 
immunoprecipitates were separated by SDS-PAGE, conducted essentially as 
previously described ( 67  ). Relevant bands were identifi  ed by autoradiography 
(24  –  48 h), the appropriate gel region was cut out, and single polypeptides 
were eluted for 24  –  36 h in three steps with 250   μ  l PBS containing 0.2% SDS 
and 50 mM dithiothreitol. Sample glycoproteins were boiled for 4 min, al-
kylated in the dark with 130 mM iodoacetamide at 37  °  C for 45 min, precip-
itated (  66  ) with trichloroacetic acid (fi  nal concentration = 12% wt/vol) for 
4 h at 4  °  C, and recovered by centrifugation at 14,000   g   for 5 min on a mi-
crofuge. Protein pellets were incubated with cold acetone at     20  °  C for 2 h, 
washed three times with cold acetone in a microfuge (14,000   g   for 5 min), 
and vacuum dried and resolubilized in SDS-PAGE or two-dimensional pep-
tide mapping sample buff  er (  68  ). 
  Two-dimensional peptide mapping.     This was conducted essentially as 
previously described (  68  ), with minor modifi  cations (  22  ). Silica gel plates 
were dried, exposed to a phosphor screen (Kodak) for 25  –  45 d, and devel-
oped on a PhosphorImager (Molecular Dynamics). 
  Detection of cytokine production by ELISA.     50   ×   10  3   IFN-      –  primed 
and unprimed mono-DCs per well were treated with diff  erent stimuli or left 
untreated. After 18 h, supernatants were collected and tested in ELISA for 
IL-12p75 (Bender), IL-23 (eBioscience), and IL-10 (Bender) production. 
Supernatants from T cells were evaluated for IFN-     (B133.1 and B133.5 
mAbs) and IL-17 (Invitrogen) production. 
  Quantitation of mRNA accumulation.     mRNA accumulation was ana-
lyzed using the QuantiGene multiplex assay (Panomics). mono-DCs were 
lysed 3, 6, and 12 h after treatment in lysis mixture. Transcript expression in 
cell lysates was detected and quantitated according to the manufacturer  ’  s in-
structions. Expression of target-specifi  c RNA molecules was calculated as the 
mean values from triplicate cultures and normalized against peptidylprolyl 
isomerase B (cyclophilin B). 
  Statistical analysis.     Results were compared using a two-tailed paired Stu-
dent  ’  s   t   test. Diff  erences were considered signifi  cant at P   <   0.05. 
  Online supplemental material.     The supplemental fi  gures provide infor-
mation on the assembly of IL-12 and IL-23 (Fig. S1), the eff  ect of gly-
cosylation on the secretion of IL-12 and IL-23 (Fig. S2), the production 
of IL-12 and IL-23 in CD1c  +   DCs and monocyte-enriched PBMCs (Fig. 
S3), the production of IL-12 p75 and p40 in NOD2      /      Crohn  ’  s disease 
patients (Fig. S4), and a model for the diff  erential regulation of IL-12 and 
IL-23 production in mono-DCs by   M. tuberculosis   or zymosan (Fig. S5). 
Supplemental results and discussion provides further information regarding 
Figs. S1 and S2. Online supplemental material is available at http://www
.jem.org/cgi/content/full/jem.20071450/DC1. 
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at 80  °  C for 1 h in a water bath, and bacteria were harvested by centrifuga-
tion. After three washes in RPMI 1640 medium, the pellet was resuspended 
at a concentration of 5 mg/ml (wet weight) in RPMI 1640. The bacterial 
suspension was divided into aliquots and stored frozen at   –  80  °  C until use 
at a 1:15 dilution. 
  Cells and cell cultures.     PBMCs obtained from healthy human donors 
were separated by Ficoll-Paque density gradient centrifugation. Leukopaks 
of peripheral blood from healthy donors were collected according to the 
National Institutes of Health approved institutional review board protocols, 
or were obtained from the blood bank of the University of Verona as dis-
carded material after preparation of therapeutic blood products. Monocytes 
were enriched from PBMCs by depletion of T cells using E-rosetting with 
neuraminidase-treated sheep red blood cells and density gradient separation 
on Ficoll-Paque. The enriched cell suspension contained   >  70% monocytes, 
as evaluated by direct immunofl  uorescence with anti-CD14 mAb (Becton 
Dickinson). Cells were resuspended in RPMI 1640 medium supplemented 
with 10% heat-inactivated, low-endotoxin FCS and   l-  glutamine, and were 
treated for 24 h with 12 ng/ml IL-4 (10  8   U/mg; Schering-Plough Bio-
pharma) and for 18 h with 1,000 U/ml IFN-     (provided by Roussel Uclaf). 
mono-DCs were obtained by a 5-d culture of plastic-adherent PBMCs in 
medium with 12 ng/ml IL-4 and 50 ng/ml GM-CSF (10  7   U/mg; Schering-
Plough Biopharma) and by an 18-h culture with or without 1,000 U/ml 
IFN-    . CD1c  +   DCs were obtained from PBMCs by depletion of CD19  +   
B lymphocytes with CD19 microbeads, followed by positive selection with 
CD1c-biotin and antibiotin microbeads, according to the manufacturer  ’  s 
procedure (Miltenyi Biotec). Purifi  ed cells (  >  98% CD1c  +  ), as evaluated by 
labeling cells with streptavidin-PE, were treated with or without IFN-     
for 4 h. 
  CD4  +  , CD45RO        naive T lymphocytes were obtained from PBMCs by 
negative depletion using a naive CD4  +   T cell enrichment kit, according to 
the manufacture  ’  s procedure (StemCell Technologies Inc.). CD4  +  , CD45RO        
(  >  99% CD4  +   and   <  2% CD45RO  +  ) cells were stimulated with plastic-bound 
anti-CD3 mAb (eBioscience) and anti-CD28 in the presence of supernatants 
from variously stimulated mono-DCs. After 5 d, T cells were washed and 
stimulated with soluble anti-CD3 mAb and 10 ng/ml PMA. Supernatants 
were collected after 18 h. 
  NOD2 genotyping.     Three Crohn  ’  s disease patients homozygous for the 
NOD2 L1007fs variant were selected among the patient group described in 
Giachino et al. (  28  ). In healthy controls, the presence of the major Crohn  ’  s 
disease  –  associated variants R702W, G908R, and L1007fs was excluded, as 
previously described (  28  ). The study was conducted under the approval of 
the ethical review board of San Giovanni Battista Hospital of Torino. Writ-
ten informed consent in accordance with the Declaration of Helsinki was 
obtained from each participant. 
  [  35  S]Methionine radiolabeling.     For continuous labeling with [  35  S]methionine, 
monocyte-enriched PBMCs, mono-DCs, and CD1c  +   DCs were resuspended 
in methionine-free RPMI 1640 supplemented with 10% FCS and 7% nor-
mal RPMI 1640 as a source of cold methionine, and were incubated for 
18 h with 60   μ  Ci/ml [  35  S]methionine (1,200 Ci/mmol; NEN-DuPont) and 
stimuli. In some experiments, IFN-      –  primed mono-DCs were preincu-
bated for 1 h with tunicamycin (TM) (  22  ) at 2   μ  g/ml in methionine-free 
medium, followed by incubation for 17 h with [  35  S]methionine and LPS in 
the presence of 2   μ  g/ml TM. The viability of TM-treated cells, as deter-
mined by Trypan blue exclusion, did not diff  er from that of control cells and 
was always   >  95%. Radiolabeled antigens were isolated and purifi  ed as de-
scribed in the following paragraphs. 
  Immunoprecipitation of radiolabeled IL-12 and IL-23.     All proce-
dures (  66  ) were performed at 4  °  C. Cell-culture supernatants were recov-
ered, centrifuged to eliminate residual cells, and immunoprecipitated after 
the addition of a 10% TBS solution (10 mM Tris-HCl [pH 8.2], 150 mM 
NaCl, and 0.02% NaN3) containing 1% Nonidet P-40 and 10   μ  g/ml leu-1460 IL-12 AND IL-23 PRODUCTION IN HUMAN DENDRITIC CELLS | Gerosa et al.
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